What should I know first?
Quetiapine acts at several receptors, which are proteins that respond to chemical messages. This lesson uses immediate-release Seroquel tablets and describes receptor pharmacology separately from the medicine’s clinical uses.
Immediate-release and extended-release quetiapine have distinct product labeling. A receptor lesson cannot establish an approved use, choose a formulation or predict a person’s experience.
This is a mechanism lesson, not a complete medicine guide. A diagram cannot choose treatment, predict your response, or tell you how to change a prescription.
How Brain Cells Communicate
Chemical messengers such as dopamine and serotonin can activate receptors on cells. Receptor activation can change cell signaling. A receptor’s name identifies a type of protein, not a diagnosis or a measure of how someone feels.
Dopamine · D2 receptor
- Dopamine
A messenger can change signaling through its receptor.
- D2 receptor
This receptor symbol identifies a function, not a molecular structure.
- Cell response
The arrow represents a signaling response, not movement through a pore.
Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.
Serotonin · 5-HT2 receptor
- Serotonin
A messenger can change signaling through its receptor.
- 5-HT2 receptor
This receptor symbol identifies a function, not a molecular structure.
- Cell response
The arrow represents a signaling response, not movement through a pore.
Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.
About this illustration
A chemical messenger can activate a receptor and change signaling inside a cell.
How the Medication Changes Signaling
Quetiapine has antagonist actions at dopamine D2 and serotonin 5-HT2 receptors. An antagonist can reduce activation of a receptor by its usual messenger. These actions may contribute to clinical effects, but the label states that the mechanism for the listed indications is unclear.
The body also makes norquetiapine, an active metabolite. Quetiapine and this metabolite interact with several receptor types, including histamine and adrenergic receptors. The two are related but are not identical compounds.
Explore the mechanism
What can receptor antagonism explain—and what can it not?
Dopamine · D2 receptor
- Dopamine
A messenger can change signaling through its receptor.
- D2 receptor
This receptor symbol identifies a function, not a molecular structure.
- Cell response
The arrow represents a signaling response, not movement through a pore.
Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.
Serotonin · 5-HT2 receptor
- Serotonin
A messenger can change signaling through its receptor.
- 5-HT2 receptor
This receptor symbol identifies a function, not a molecular structure.
- Cell response
The arrow represents a signaling response, not movement through a pore.
Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.
Dopamine · D2 receptor
- Dopamine
A messenger can change signaling through its receptor.
- D2 receptor
This receptor symbol identifies a function, not a molecular structure.
- Cell response
The arrow represents a signaling response, not movement through a pore.
Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.
Serotonin · 5-HT2 receptor
- Serotonin
A messenger can change signaling through its receptor.
- 5-HT2 receptor
This receptor symbol identifies a function, not a molecular structure.
- Cell response
The arrow represents a signaling response, not movement through a pore.
Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.
Dopamine · D2 receptor
- Dopamine
A messenger can change signaling through its receptor.
- D2 receptor
This receptor symbol identifies a function, not a molecular structure.
- Quetiapine: activation opposed
The crossbar marks opposition to receptor activation, not permanent closure.
Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.
Serotonin · 5-HT2 receptor
- Serotonin
A messenger can change signaling through its receptor.
- 5-HT2 receptor
This receptor symbol identifies a function, not a molecular structure.
- Quetiapine: activation opposed
The crossbar marks opposition to receptor activation, not permanent closure.
Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.
What this model cannot tell us
Clinical mechanism unclear
- Clinical mechanism unclear The clinical explanation remains uncertain.
- Limits of inference An experimental result does not by itself predict one person’s treatment response.
Static overview. Start the steps when you are ready.
Reduced motion is on. Use the step buttons or read the complete sequence.
Guide to the illustration: Outlines identify a cell membrane or target; arrows mark the direction explained in each caption. Medicine symbols are labels, not measured shapes or binding poses. No quantity, size or rate is to scale.
Read the complete sequence
- A receptor receives a message. A chemical messenger can activate a receptor and change signaling inside a cell.
- Quetiapine: antagonist action. Quetiapine can oppose activation at D2 and 5-HT2 receptors. This outline is a teaching symbol, not a binding pose.
- Many actions, uncertain benefit. The active metabolite and other targets add complexity. Binding data alone do not predict treatment response.
Evidence and model limits
Quetiapine and active-metabolite actions from product labeling. No affinity numbers, cross-assay ranking, occupancy or clinical inference from molecular shape.
Two receptor examples cannot represent all quetiapine actions or establish the mechanism of clinical benefit.
A Closer Look at the Molecular Level
The labels report receptor-binding measurements from experimental work. Such measurements are not a ranking of clinical effectiveness and do not show receptor occupancy in an individual. This lesson deliberately uses no numerical binding hierarchy.
Known receptor actions coexist with uncertainty about how those actions combine to produce clinical benefit. Sedation is an effect to assess, not evidence that an illness has been treated. No measured protein structure or docking pose is shown.
Sources and References
The sources below support the specific medicine and experimental context described here. Drawings are original qualitative teaching models; positions, arrows and timing do not give atomic geometry, occupancy or rates.
Article Information
- Content updated
- 2026-10-16
- Sources checked
- 2026-10-16
- Publication status
- Published
Illustration information
- What can receptor antagonism explain—and what can it not?
Checked 2026-10-16 · Created for Psychiatry Atlas · Original project artwork

